FDANews
www.fdanews.com/articles/190899-nanobiotixs-nanoparticle-radioenhancer-receives-ce-mark

Nanobiotix’s Nanoparticle Radioenhancer Receives CE Mark

April 10, 2019

Nanobiotix has earned the CE Mark for its Hensify radioenhancer, an injected nanoparticle device that amplifies the effectiveness of standard radiotherapy.

The device introduces a new mechanism of action that, in combination with radiotherapy, helps to physically eliminate tumors and kick a patient’s immune system into gear for local control and systemic disease treatment.

Hensify is an aqueous suspension of crystalline hafnium oxide nanoparticles that is injected into a tumor after initial radiotherapy treatment.

View today's stories